Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
Merck axes main asset from $1.9B Pandion buyout
MK-6194 was being studied in a pair of phase 2 trials for lupus and vitiligo. Merck picked up the asset from Pandion in a $1.9 billion acquisition.
Gabrielle Masson
Jul 29, 2025 2:42pm
Quoin shelves 2 assets to build around lead program
Jul 29, 2025 10:25am
AstraZeneca drops lead TCR therapy from $200M Neogene buy
Jul 29, 2025 4:13am
Galapagos builds island of cell therapies amid pipeline pruning
Jul 24, 2025 10:59am
Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Jul 24, 2025 5:00am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
